冠脉CT衍生FFR在实际临床决策中的应用与影响:ADVANCE注册研究
ADVANCE注册研究前瞻性纳入5083例有症状且CCTA显示动脉粥样硬化的患者,评估CCTA联合选择性FFRCT诊断路径对治疗决策、后续有创冠脉造影、血运重建及90天MACE的影响。结果显示FFRCT使66.9%患者的治疗计划较单纯CCTA发生改变,FFRCT≤0.80者中有创冠脉造影非阻塞性病变比例更低、血运重建率更高,且FFRCT>0.80者90天内无死亡/心肌梗死发生。
要点
- FFRCT使约三分之二患者的治疗决策较单纯CCTA发生改变。
- FFRCT≤0.80者有创冠脉造影非阻塞性病变比例显著低于FFRCT>0.80者。
- FFRCT>0.80者90天内无死亡/心肌梗死,提示低风险。
核心结论
- 在大规模国际多中心人群中,FFRCT较单纯CCTA改变约三分之二患者的治疗推荐,与更少阴性有创冠脉造影相关,可预测血运重建并识别90天内低不良事件风险者。
研究设计与样本
- 记录人口学、症状状态、CCTA与FFRCT结果、治疗计划及90天结局。
主要发现
- 核心实验室单纯CCTA与CCTA联合FFRCT管理计划之间发生治疗分类改变的患者比例为66.9%(CI:64.8-67.6)。
- 接受有创冠脉造影者中,FFRCT≤0.80组非阻塞性冠状动脉病变比例为14.4%,低于FFRCT>0.80组的43.8%(比值比0.19,CI:0.15-0.25,P<0.001)。
- 接受有创冠脉造影且FFRCT≤0.80的受试者中72.3%接受了血运重建。
- FFRCT>0.80者(n=1529)90天内无死亡/心肌梗死发生;FFRCT≤0.80者发生19例(0.6%)MACE(风险比19.75,CI:1.19-326,P=0.0008)和14例(0.3%)死亡/心肌梗死(风险比14.68,CI:0.88-246,P=0.039)。
临床怎么用
- 对CCTA显示动脉粥样硬化的稳定胸痛患者,可结合选择性FFRCT辅助治疗决策,以减少不必要的有创冠脉造影。
- FFRCT>0.80提示90天内不良事件风险低,可支持保守管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Non-invasive assessment of stable chest pain patients is a critical determinant of resource utilization and clinical outcomes. Increasingly coronary computed tomography angiography (CCTA) with selective CCTA-derived fractional flow reserve (FFRCT) is being used. The ADVANCE Registry, is a large prospective examination of using a CCTA and FFRCT diagnostic pathway in real-world settings, with the aim of determining the impact of this pathway on decision-making, downstream invasive coronary angiography (ICA), revascularization, and major adverse cardiovascular events (MACE). METHODS AND RESULTS: A total of 5083 patients with symptoms concerning for coronary artery disease (CAD) and atherosclerosis on CCTA were enrolled at 38 international sites from 15 July 2015 to 20 October 2017. Demographics, symptom status, CCTA and FFRCT findings, treatment plans, and 90 days outcomes were recorded. The primary endpoint of reclassification between core lab CCTA alone and CCTA plus FFRCT-based management plans occurred in 66.9% [confidence interval (CI): 64.8-67.6] of patients. Non-obstructive coronary disease was significantly lower in ICA patients with FFRCT ≤0.80 (14.4%) compared to patients with FFRCT >0.80 (43.8%, odds ratio 0.19, CI: 0.15-0.25, P < 0.001). In total, 72.3% of subjects undergoing ICA with FFRCT ≤0.80 were revascularized. No death/myocardial infarction (MI) occurred within 90 days in patients with FFRCT >0.80 (n = 1529), whereas 19 (0.6%) MACE [hazard ratio (HR) 19.75, CI: 1.19-326, P = 0.0008] and 14 (0.3%) death/MI (HR 14.68, CI 0.88-246, P = 0.039) occurred in subjects with an FFRCT ≤0.80. CONCLUSIONS: In a large international multicentre population, FFRCT modified treatment recommendation in two-thirds of subjects as compared to CCTA alone, was associated with less negative ICA, predicted revascularization, and identified subjects at low risk of adverse events through 90 days.
引用
- Fairbairn TA, Nieman K, Akasaka T, et al. Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry. Eur Heart J. 2018. PMID: 30165613. doi:10.1093/eurheartj/ehy530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。